Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
06:19pm, Friday, 05'th Jun 2026
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
10:10am, Friday, 05'th Jun 2026
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
Five Boring Dividend Aristocrats That Quietly Pay $36,000 a Year on $850,000 Without a Single Yield Trap
09:18am, Friday, 05'th Jun 2026
Replacing $36,000 a year in income is roughly equivalent to generating the cash flow from a maximum Social Security benefit for a single retiree, or about $3,000 a month before taxes. A 66-year-old wi
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
08:45am, Friday, 05'th Jun 2026
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target
08:19am, Friday, 05'th Jun 2026
Five Dividend Aristocrats with streaks ranging from 54 to 70 consecutive years of payout hikes are currently trading below Wall Street's consensus price targets, and four of the five just beat their m
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
06:45pm, Thursday, 04'th Jun 2026
In the latest trading session, Johnson & Johnson (JNJ) closed at $228.17, marking a +2.21% move from the previous day.
How to Maximize Dividend Income in Retirement Before RMDs Change the Math
10:00am, Thursday, 04'th Jun 2026
At the 24% federal bracket, a portfolio throwing off $40,000 in high-yield dividend income hands roughly $9,600 to the IRS every year when those shares sit in a taxable account treated as ordinary inc
Can Pure Dividend Stocks Replace a $110,000 Dual-Income Household Income? Here’s What It Would Take
06:51am, Thursday, 04'th Jun 2026
A combined household income of $110,000 is close to the national norm for a two-earner household. For a 56-year-old couple hoping to retire at age 60 and fund their lifestyle entirely through dividend
Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic Par
Are You Looking for a High-Growth Dividend Stock?
12:51pm, Wednesday, 03'rd Jun 2026
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:00am, Wednesday, 03'rd Jun 2026
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
This Is What a $1 Million Dividend Portfolio Pays After Taxes
07:45am, Wednesday, 03'rd Jun 2026
At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
01:00am, Wednesday, 03'rd Jun 2026
Johnson and Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Johnson and Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2
Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodi
